Aidoc announced today that it is partnering with Imbio in an effort to provide an end-to-end AI solution for pulmonary embolism (PE).
The goal of the collaboration between Aidoc and Imbio is to improve the efficiency and quality of pulmonary embolism detection and treatment, according to a news release.
“Achieving the value of AI in clinical practice requires end-to-end solutions which consolidate the various AI results and tailor their delivery to the clinical needs,” Aidoc VP of business development Tom Valent said in the release. “Imbio and Aidoc have joined forces to develop a complete PE solution to radiologists and interventionalists, both in terms of the suite of relevant algorithms and a seamless workflow native to each type of physician.”
Aidoc’s AI solution for providing real-time notifications for patients with suspected pulmonary embolism is already FDA-cleared, while Imbio is developing imaging analysis intended for the automatic calculation of RV/LV ratio.
Together, the two companies plan to develop investigational technology to offer thoracic radiologists and pulmonary embolism management programs timely notification of pulmonary embolism cases combined with automated RV/LV ratio calculations to potentially improve patient severity assessment and expedite treatment.
“Automating and presenting RV/LV ratio measurements to PE intervention teams has the ability to aid in patient care,” Imbio director of marketing & sales Mike Hostetler said. “Combining this with Aidoc’s always-on AI platform is intended to trigger targeted alerts to the relevant physicians, enhancing the synchronization of intervention teams and the quality of treatment provided to the patients.”
